CTSB and neoplasm: These observations also emphasise the potential to select patients for early clinical trial involving nanomedicine therapy that are most likely to respond, i.e. by use of clinical imaging to verify functional EPR [43], and monitoring of tumour biopsy samples for biomarkers relevant to activating conditions, e.g. in this case cathepsin B.